Ipilimumab (10 mg/kg)titleipilimumab alonetitleipilimumab plus gp100titletremelimumabtitleipilimumab plus SoCtitleinterferon alphatitleplacebotitleStandard of Care (SoC)titleplacebo plus SoCtitlegp100titleA3671009, 2013 NCT00257205 mML - L1 - all population 328/327Ascierto (ipi 10 vs 3 mg/kg), 2017 NCT01515189 mML - L2 - all population 365/362CA184-004, 2011 NCT00261365 mML - L2 - all population 40/42MDX010 Ipi vs gp100, 2010 NCT00094653 mML - L2 - all population 137/136MDX010 Ipi plus gp100 vs gp100, 2010 NCT00094653 mML - L2 - all population 403/136MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 NCT00094653 mML - L2 - all population 403/137CA184-024, 2011 NCT00324155 mML - L2 - all population 250/252E1609 (ipi10), 2020 NCT01274338 mML - NA - all population 511/636EORTC 18071, 2015 NCT00636168 mML - NA - all population 475/476E1609 (ipi3), 2020 NCT01274338 mML - NA - all population 523/636

Pathology:  mML - L1 - all population;   mML - L2 - all population;   mML - NA - all population; 

mML - L1 - all populationmML - L2 - all populationmML - NA - all population
A3671009, 2013Ascierto (ipi 10 vs 3 mg/kg), 2017CA184-004, 2011MDX010 Ipi vs gp100, 2010MDX010 Ipi plus gp100 vs gp100, 2010MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010CA184-024, 2011E1609 (ipi10), 2020EORTC 18071, 2015E1609 (ipi3), 2020
Ipilimumab (10 mg/kg)4T1T1T1T1
ipilimumab alone2T0T0T1T0T1
ipilimumab plus gp1002T1T1
tremelimumab1T1
ipilimumab plus SoC1T1
interferon alpha0T0T0
placebo0T0
Standard of Care (SoC)0T0
placebo plus SoC0T0
gp1000T0T0